KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation
Condition: Non-Small Cell Lung Cancer
Sponsor: Mirati Therapeutics, Inc.
Full Title
Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Study Treatment
KRAS G12C inhibitor adagrasib in combination with pemetrexed and pembrolizumab.
Eligibility/Info
Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer treated with 4 cycles of platinum-based chemotherapy and pembrolizumab as first line treatment.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
